Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Phosphodiesterase 4D inhibitors limit prostate cancer growth potential.

Powers GL, Hammer KD, Domenech M, Frantskevich K, Malinowski RL, Bushman W, Beebe DJ, Marker PC.

Mol Cancer Res. 2015 Jan;13(1):149-60. doi: 10.1158/1541-7786.MCR-14-0110. Epub 2014 Aug 22.

2.

Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.

Pullamsetti SS, Banat GA, Schmall A, Szibor M, Pomagruk D, Hänze J, Kolosionek E, Wilhelm J, Braun T, Grimminger F, Seeger W, Schermuly RT, Savai R.

Oncogene. 2013 Feb 28;32(9):1121-34. doi: 10.1038/onc.2012.136. Epub 2012 Apr 23.

PMID:
22525277
5.

Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen.

Rahrmann EP, Collier LS, Knutson TP, Doyal ME, Kuslak SL, Green LE, Malinowski RL, Roethe L, Akagi K, Waknitz M, Huang W, Largaespada DA, Marker PC.

Cancer Res. 2009 May 15;69(10):4388-97. doi: 10.1158/0008-5472.CAN-08-3901. Epub 2009 Apr 28.

6.

Aberrant DNA Methylation of Phosphodiesterase [corrected] 4D Alters Airway Smooth Muscle Cell Phenotypes.

Lin AH, Shang Y, Mitzner W, Sham JS, Tang WY.

Am J Respir Cell Mol Biol. 2016 Feb;54(2):241-9. doi: 10.1165/rcmb.2015-0079OC. Erratum in: Am J Respir Cell Mol Biol. 2016 Apr;54(4):597.

7.

Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling.

Li YF, Cheng YF, Huang Y, Conti M, Wilson SP, O'Donnell JM, Zhang HT.

J Neurosci. 2011 Jan 5;31(1):172-83. doi: 10.1523/JNEUROSCI.5236-10.2011.

8.

Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression.

Gowda PS, Deng JD, Mishra S, Bandyopadhyay A, Liang S, Lin S, Mahalingam D, Sun LZ.

Mol Cancer Res. 2013 Nov;11(11):1448-61. doi: 10.1158/1541-7786.MCR-13-0278. Epub 2013 Aug 29.

9.

TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.

Ibuki N, Ghaffari M, Pandey M, Iu I, Fazli L, Kashiwagi M, Tojo H, Nakanishi O, Gleave ME, Cox ME.

Int J Cancer. 2013 Oct 15;133(8):1955-66. doi: 10.1002/ijc.28193. Epub 2013 May 6.

10.

Phosphodiesterase 4D acts downstream of Neuropilin to control Hedgehog signal transduction and the growth of medulloblastoma.

Ge X, Milenkovic L, Suyama K, Hartl T, Purzner T, Winans A, Meyer T, Scott MP.

Elife. 2015 Sep 15;4. doi: 10.7554/eLife.07068.

11.
12.

Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.

Ghosh PM, Malik SN, Bedolla RG, Wang Y, Mikhailova M, Prihoda TJ, Troyer DA, Kreisberg JI.

Endocr Relat Cancer. 2005 Mar;12(1):119-34.

13.

Tanshinones from Chinese medicinal herb Danshen (Salvia miltiorrhiza Bunge) suppress prostate cancer growth and androgen receptor signaling.

Zhang Y, Won SH, Jiang C, Lee HJ, Jeong SJ, Lee EO, Zhang J, Ye M, Kim SH, Lü J.

Pharm Res. 2012 Jun;29(6):1595-608. doi: 10.1007/s11095-012-0670-3. Epub 2012 Jan 27.

PMID:
22281759
14.

Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models.

Squillace RM, Miller D, Wardwell SD, Wang F, Clackson T, Rivera VM.

Int J Oncol. 2012 Aug;41(2):425-32. doi: 10.3892/ijo.2012.1487. Epub 2012 May 18.

15.

NF-kappaB regulates androgen receptor expression and prostate cancer growth.

Zhang L, Altuwaijri S, Deng F, Chen L, Lal P, Bhanot UK, Korets R, Wenske S, Lilja HG, Chang C, Scher HI, Gerald WL.

Am J Pathol. 2009 Aug;175(2):489-99. doi: 10.2353/ajpath.2009.080727. Epub 2009 Jul 23.

16.

Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.

Long BJ, Grigoryev DN, Nnane IP, Liu Y, Ling YZ, Brodie AM.

Cancer Res. 2000 Dec 1;60(23):6630-40.

17.

Sonic hedgehog and androgen signaling in tumor and stromal compartments drives epithelial-mesenchymal transition in prostate cancer.

Yamamichi F, Shigemura K, Behnsawy HM, Meligy FY, Huang WC, Li X, Yamanaka K, Hanioka K, Miyake H, Tanaka K, Kawabata M, Shirakawa T, Fujisawa M.

Scand J Urol. 2014 Dec;48(6):523-32. doi: 10.3109/21681805.2014.898336. Epub 2014 Mar 19.

PMID:
25356787
18.

Perlecan, a candidate gene for the CAPB locus, regulates prostate cancer cell growth via the Sonic Hedgehog pathway.

Datta MW, Hernandez AM, Schlicht MJ, Kahler AJ, DeGueme AM, Dhir R, Shah RB, Farach-Carson C, Barrett A, Datta S.

Mol Cancer. 2006 Mar 1;5:9.

19.

PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.

Kaarbø M, Mikkelsen OL, Malerød L, Qu S, Lobert VH, Akgul G, Halvorsen T, Maelandsmo GM, Saatcioglu F.

Cell Oncol. 2010;32(1-2):11-27. doi: 10.3233/CLO-2009-0487.

20.

Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer.

Hamilton TK, Hu N, Kolomitro K, Bell EN, Maurice DH, Graham CH, Siemens DR.

World J Urol. 2013 Apr;31(2):325-30. doi: 10.1007/s00345-012-0848-7. Epub 2012 Mar 2.

PMID:
22383129

Supplemental Content

Support Center